Menu

Home
The Marketplace
Advancing Drug Discovery with Protein Degrader Screens

Advancing Drug Discovery with Protein Degrader Screens

Researchers use an automated immunoassay platform to analyze Degrader panels!

The Scientist

Mar 3, 2021

Advancing Drug Discovery with Protein Degrader Screens

Multimedia

April 2021 Interactive Crossword

Infographic: Steps in Cancer Metastasis

April 2021

Advancing Against Metastasis

Cancer cells can spread early and lie dormant for years

Sponsored Content

LabQuizzes

Webinars

Videos

Infographics

eBooks

How Infectious Diseases Affect the Brain

From a loss of taste to dementia, infectious agents cause an array of neurological symptoms.

Delivery of Oncolytic Immunotherapy by MSCs Enhances CAR-T Cell Anti-Tumor Activity

Katie McKenna will discuss how oncolytic viral therapy enhances CAR-T cell killing of cancer cells.

Cancer Vaccines: Raising a T Cell Army

Vaccines against various forms of cancer prime the immune system to attack.

Checking Checkpoints for Treating Cancer

Researchers devise strategies to improve checkpoint inhibitor therapy and predict patient response.

Marketplace

Sponsored Product Updates

Synthego Launches Eclipse Platform to Accelerate Research and Development of Next-generation Medicines

First-of-its-kind Platform Enables Scalable CRISPR-based Cell Engineering

Making the Most Out of the Ultraviolet Laser: How BD Horizon Brilliant™ Ultraviolet Dyes Drive Discovery

Flow cytometry is a binary system, where cells are either positive or negative for a specific marker when using an appropriate fluorescent dye to detect a specific antigen.

The Power of Discovery

Harnessing insights into heritable mutations from whole-exome sequencing data.

Using Multicolor Flow Cytometry for COVID-19 Research

Designing multicolor flow cytometry panels to characterize immunological changes observed in COVID-19 patients.